Please assess the completion status of the following clinical trial:

Trial Title: A PK and Salvage Study for Children With HIV-infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed HIV-1 infection by HIV-DNA PCR if \< 18 months old or by HIV ELISA if greater than or equal to 18 months old~2. Subject is less than or equal to 16 years of age at the day of the first dosing.~3. Subject is failing a current NRTI and/or NNRTI containing regimen and is naïve to protease inhibitor containing therapy.~4. Results of biochemistry and haematology testing should be within pre-specified ranges.~5. Subject is able to swallow capsules~6. Caretaker(s) is/are able and willing to sign the Informed Consent Form prior to screening evaluations.~Exclusion Criteria:~1. History of sensitivity/idiosyncrasy to lopinavir, ritonavir, saquinavir or chemically related compounds or excipients which may be employed in the trial.~2. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.~3. Inability of both child and caregiver(s) to understand the nature and extent of the trial and the procedures required.~4. Use of any of concomitant medication, including the drug listed below, that may interfere with the pharmacokinetics of LPV/r or SQV.~   * NNRTIs~  * Rifampicin~  * Rifabutin~  * Phenobarbital~  * Phenytoine~  * Carbamazepine~  * Dexamethasone~  * Ketoconazole~  * Clarithromycin~5. Pregnancy

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- double-boosted PI (Type: OTHER): double-boosted protease inhibitor combination

Based on this trial design, predict the completion outcome and termination type (if applicable).